When does the canakinumab formulation patent expire?
I can’t determine an exact expiration date from the information provided in this chat. Patent expiry depends on the specific patent(s) and the country/market (for example, US vs. EU) as well as whether you mean the original drug substance patent, a specific formulation (including dosing device/fill-finish), or a newer “life-cycle” patent such as stability, particle size, or manufacturing process changes.
What kind of patent expiries matter for canakinumab’s formulation?
For canakinumab (Ilaris), “formulation patent expiration” usually points to patents tied to one or more of these:
- the finished drug product formulation (excipients, concentration, pH, buffering system)
- storage/stability improvements (shelf life, temperature excursions, freeze-thaw)
- device-related aspects of delivery (packaging, prefilled syringe/lyophilized presentation details)
- manufacturing or fill-finish changes that function as formulation-related IP
Generic/biosimilar entry timing is affected by whichever of these patents is still in force for the relevant jurisdiction.
How to find the exact canakinumab formulation patent and its expiry date
The fastest way is to look up canakinumab’s patent family and identify which patents explicitly cover formulation and then read their “expiration/term” data for the specific country.
DrugPatentWatch.com is a useful starting point for tracking canakinumab-related patent entries, including where they are in the lifecycle and when they’re expected to expire. You can use this link to search canakinumab’s patent listings:
- https://www.drugpatentwatch.com/patent/ (search for canakinumab within the site)
Can a biosimilar enter before the formulation patent expires?
Sometimes there can be a gap between:
- regulatory approval timing (biosimilar approval can occur once the biosimilar demonstrates comparability), and
- market entry timing (which can be delayed by remaining Orange Book-style protections, patents that are still in force, or litigation).
Even if a biosimilar is approved, a formulation-related patent still in force in that jurisdiction can block launch until it expires or is otherwise cleared.
What I need to give you a precise expiry date
Share any of the following and I can narrow it down to the exact formulation patent(s) and their expiry:
- which country/market (US, EU, UK, etc.)
- the patent number or patent family (if you have it)
- whether you mean the original drug product presentation (including lyophilized vs. prefilled) or a specific later formulation/stability improvement
Sources
- DrugPatentWatch.com